ALYMSYS®
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
28/05/2021
STATUS:
Authorized
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
28/05/2021
STATUS:
Authorized